NORCURON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORCURON (NORCURON).
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and inducing skeletal muscle paralysis.
| Metabolism | Primarily deacetylated in the liver to 3-desacetylvecuronium (active metabolite) and other metabolites; minor renal elimination. |
| Excretion | Approximately 40-50% of the dose is excreted unchanged in urine within 24 hours; 20-30% is eliminated in feces as unchanged drug and metabolites; minor biliary excretion. |
| Half-life | Terminal elimination half-life is approximately 1.3-2.2 hours in adults; prolonged in hepatic or renal impairment (up to 3-4 hours in renal failure). |
| Protein binding | Approximately 30-40% bound to albumin and gamma globulins. |
| Volume of Distribution | Volume of distribution: 0.2-0.3 L/kg; reflects primarily extracellular fluid distribution. |
| Bioavailability | Bioavailability: 100% intravenous; not administered via other routes. |
| Onset of Action | Intravenous: 2-3 minutes for intubating dose (0.08-0.1 mg/kg); 3-5 minutes for lower doses. |
| Duration of Action | Duration of neuromuscular block: 20-35 minutes after initial intubating dose; recovery to 25% of control twitch height in 25-40 minutes; prolonged in renal failure or with volatile anesthetics. |
| Action Class | Skeletal muscle relaxant- Peripherally acting |
| Brand Substitutes | Samvec 4mg Injection, Gervec 4mg Injection, Kabivec 4mg Injection, Vecuron 4mg Injection, Flexivec 4mg Injection, Veroni 10mg Injection, Samvec 10mg Injection, Gervec 10mg Injection, Vibro 10mg Injection, Lyvec 10mg Injection |
0.08-0.1 mg/kg IV bolus for intubation; maintenance 0.01-0.015 mg/kg IV every 30-60 min as needed or continuous infusion at 0.06-0.12 mg/kg/hr.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: no adjustment required; GFR <10 mL/min: consider reduced dose and extended intervals due to prolonged duration of action. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B/C: dose reduction by 50% and monitor for prolonged neuromuscular blockade. |
| Pediatric use | Neonates: 0.05-0.1 mg/kg IV; Infants/Children: 0.08-0.1 mg/kg IV; maintenance 0.01-0.02 mg/kg IV as needed. |
| Geriatric use | No specific dose adjustment; may have prolonged duration of action; use lower initial doses (0.06-0.08 mg/kg) and titrate to effect. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORCURON (NORCURON).
| Breastfeeding | Excretion in human milk unknown; M/P ratio not available. Caution advised due to potential for adverse effects in nursing infant, including gastrointestinal disturbances and neuromuscular weakness. Consider discontinuing breastfeeding or drug, taking into account importance of drug to mother. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 3 times the human dose, but fetal loss occurred at high doses. Use only if potential benefit justifies potential risk to fetus. First trimester: Risk cannot be ruled out due to lack of data. Second and third trimesters: Transient neonatal weakness if used near term; may cause respiratory depression and hypotonia. Avoid use during labor and delivery unless necessary. |
■ FDA Black Box Warning
Appropriate administration, monitoring, and reversal of neuromuscular blockade must be ensured to avoid inadequate ventilation or respiratory depression; use only by clinicians trained in airway management and resuscitation.
| Serious Effects |
["Hypersensitivity to vecuronium or any component","Known hypersensitivity to bromides"]
| Precautions | ["Risk of prolonged neuromuscular blockade in patients with hepatic impairment, renal failure, or electrolyte disorders","Potential for histamine release with rapid bolus administration","Increased sensitivity in patients with neuromuscular diseases","May cause respiratory depression requiring mechanical ventilation"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, oxygen saturation, and neuromuscular function (train-of-four) during administration. Fetal heart rate monitoring during prolonged use near term. Neonatal monitoring for signs of neuromuscular blockade (weakness, respiratory depression) if used during labor and delivery. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility was observed at doses up to 3 times the human dose. |